Caris Life Sciences secured $310 million in growth capital that will be used to expand the molecular science company’s presence in precision medicine in oncology.
Bayer is making a big bet on gene therapy with the acquisition of North Carolina-based Asklepios BioPharmaceutical (AskBio).
ADC Therapeutics SA announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for loncastuximab tesirine (Lonca) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Silicon Valley medical equipment startup Visby Medical received Emergency Use Authorization by the U.S. Food and Drug Administration for a portable PCR Covid-19 test kit, the first company to do so, according to the FDA.
Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.
Roche received authorization from the U.S. Food and Drug Administration for the company’s cobas 6800/8800 diagnostic tests for transplant patients.
Gene therapy pioneer uniQure launched the first-in-human adeno-associated virus-based gene therapy clinical trial for Huntington’s disease.
Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.
Cambridge-based Magenta Therapeutics entered a non-exclusive research and clinical collaboration agreement with Beam Therapeutics.
British researchers will study the genes of thousands of ill COVID-19 patients to try to crack one of the most puzzling riddles of the novel coronavirus: why does it kill some people but give others not even a mild headache?
